CIWA-Ar

Max score 67. No Rx for score under 10

Assesses the severity of alcohol withdrawal symptoms to guide management.

Nausea, Vomiting
No N, no V0Mild N, no V+1Intermittent N, dry heaves+4Constant N, frequent dry heaves,V+7
Tremor
No tremor0Not visible, can be felt+1Moderate with arms extended+4Severe+7
Paroxysm Sweats
No sweat visible0Barely perceptible,palms moist+1Obvious sweat on forehead+4Drenching sweats+7
Anxiety
No anxiety, at ease0Mildly anxious+1Moderately anxious or guarded+4As in acute panic+7
Agitation
Normal activity0Somewhat more than normal+1Moderately fidgety and restless+4Constant pacing or thrashing+7
Tactile Disturb
None0Very mild+1Mild+2Moderate+3Moderately severe hallucinations+4Severe hallucinations+5Extremely severe hallucinations+6Continuous hallucinations+7
Auditory Disturb
None0Very mild+1Mild+2Moderate+3Moderately severe hallucinations+4Severe hallucinations+5Extremely severe hallucinations+6Continuous hallucinations+7
Visual Disturb
None0Very mild+1Mild+2Moderate+3Moderately severe hallucinations+4Severe hallucinations+5Extremely severe hallucinations+6Continuous hallucinations+7
HA, Fullness
Not present0Very mild+1Mild+2Moderate+3Moderately severe+4Severe+5Very severe+6Extremely severe+7
Orientation, Sensorium
Oriented, can add serially0Uncertain about date or cannot add+1Date wrong by no more than 2 days+2Date wrong by more than 2 days+3Disoriented for place or person+4

使用適応

Used to assess alcohol withdrawal severity in communicative adults and to guide symptom‑triggered benzodiazepine dosing. Validated to track withdrawal course and correlate with treatment response 1 [Level II evidence]. Symptom‑triggered protocols using CIWA‑Ar reduce benzodiazepine exposure and length of stay without added adverse events 2 [Level II evidence]. Not reliable in ICU or non‑communicative patients.

洞察と注意事項

Start with cautious, symptom‑triggered use; requires a communicative, non‑delirious, medically stable patient. It reliably tracks withdrawal severity and guides benzodiazepine dosing but is subjective and misleading in ICU, postoperative states, delirium, language barriers, or nonverbal patients 1. Overuse in low‑risk or poorly selected patients increases benzodiazepine exposure and adverse events 2. Use clinical judgment and alternative objective scales when communication is impaired.